IL144259A0 - Methods for making proteins containing free cysteine residues - Google Patents

Methods for making proteins containing free cysteine residues

Info

Publication number
IL144259A0
IL144259A0 IL14425900A IL14425900A IL144259A0 IL 144259 A0 IL144259 A0 IL 144259A0 IL 14425900 A IL14425900 A IL 14425900A IL 14425900 A IL14425900 A IL 14425900A IL 144259 A0 IL144259 A0 IL 144259A0
Authority
IL
Israel
Prior art keywords
methods
cysteine residues
proteins containing
containing free
free cysteine
Prior art date
Application number
IL14425900A
Other languages
English (en)
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22364893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144259(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Publication of IL144259A0 publication Critical patent/IL144259A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14425900A 1999-01-14 2000-01-14 Methods for making proteins containing free cysteine residues IL144259A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11604199P 1999-01-14 1999-01-14
PCT/US2000/000931 WO2000042175A1 (en) 1999-01-14 2000-01-14 Methods for making proteins containing free cysteine residues

Publications (1)

Publication Number Publication Date
IL144259A0 true IL144259A0 (en) 2002-05-23

Family

ID=22364893

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14425900A IL144259A0 (en) 1999-01-14 2000-01-14 Methods for making proteins containing free cysteine residues
IL144259A IL144259A (en) 1999-01-14 2001-07-11 Methods for making proteins containing free cysteine residues
IL194483A IL194483A0 (en) 1999-01-14 2008-10-02 Methods for making proteins containing free cysteine residues

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144259A IL144259A (en) 1999-01-14 2001-07-11 Methods for making proteins containing free cysteine residues
IL194483A IL194483A0 (en) 1999-01-14 2008-10-02 Methods for making proteins containing free cysteine residues

Country Status (12)

Country Link
EP (2) EP1144613B2 (xx)
JP (3) JP2002534119A (xx)
KR (1) KR100731826B1 (xx)
CN (1) CN1210400C (xx)
AT (1) ATE526401T1 (xx)
AU (2) AU775937B2 (xx)
BR (2) BR0008759B1 (xx)
CA (1) CA2359345A1 (xx)
ES (1) ES2373093T3 (xx)
IL (3) IL144259A0 (xx)
NZ (1) NZ513077A (xx)
WO (1) WO2000042175A1 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
DE60129432T2 (de) 2000-05-16 2008-04-17 Bolder Biotechnology, Inc., Louisville Verfahren zur rückfaltung von proteinen mit freien cysteinresten
DE60137525D1 (de) * 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
EP1352062A2 (en) * 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules
CA2438652A1 (en) * 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
JP2005528372A (ja) * 2002-03-26 2005-09-22 バイオシネクサス インコーポレイテッド 抗菌ポリマー複合体
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
EP1667708B9 (en) 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
ES2911435T3 (es) 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
SE526214C2 (sv) * 2003-02-28 2005-07-26 Amersham Biosciences Ab Ett sätt att generera metallkelaterande affinitetsligander
DE602004025799D1 (de) 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
CN1826131A (zh) * 2003-05-30 2006-08-30 森托科尔公司 利用转谷氨酰胺酶形成新的促红细胞生成素缀合物
WO2005014033A1 (en) * 2003-07-29 2005-02-17 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
AU2004311796A1 (en) * 2003-12-31 2005-07-21 Centocor, Inc. Novel recombinant proteins with N-terminal free thiol
TW200611910A (en) 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
MX2007002441A (es) * 2004-08-31 2007-05-04 Pharmacia & Upjohn Co Llc Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
PH12014500352A1 (en) 2004-11-12 2015-07-20 Bayer Healthcare Llc Site-directed modification of fviii
WO2006089228A2 (en) 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP2213733A3 (en) * 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
JP5792951B2 (ja) 2010-12-16 2015-10-14 キヤノン株式会社 振動型アクチュエータの制御装置
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
WO2013095905A1 (en) * 2011-12-19 2013-06-27 Genzyme Corporation Thyroid stimulating hormone compositions
CN103184208B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
SG11201502511YA (en) * 2012-09-04 2015-05-28 Republic Polytechnic Isolated oligonucleotides, methods and kits for detection, identification and/or quantitation of chikungunya and dengue viruses
ES2869309T3 (es) * 2013-12-13 2021-10-25 Novo Nordisk Healthcare Ag Método para la conjugación de proteínas con tioéter
KR102639037B1 (ko) * 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
WO2016187026A1 (en) * 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
HUE053956T2 (hu) * 2015-08-12 2021-08-30 Pfizer Sapkázott és nem sapkázott ellenanyag-ciszteinek és alkalmazásuk ellenanyagdrog konjugálásban
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
EP3580234A1 (en) * 2017-02-08 2019-12-18 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
CN111172184A (zh) * 2020-03-10 2020-05-19 大连理工大学 一种基于基因修饰得到人重组干扰素的融合基因、融合蛋白及其制备方法
CN112812963A (zh) * 2021-01-28 2021-05-18 美康生物科技股份有限公司 一种总同型半胱氨酸测试卡
CN115417917A (zh) * 2021-05-30 2022-12-02 中国科学院上海药物研究所 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5016321B1 (xx) * 1969-05-10 1975-06-12
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
JPH01132598A (ja) * 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5130418A (en) * 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5837539A (en) † 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE4113750A1 (de) * 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
CA2116774C (en) * 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
WO1993020200A1 (en) † 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU6048294A (en) 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
CA2160154A1 (en) 1993-04-07 1994-10-13 George N. Cox Methods of using insulin-like growth factor binding proteins
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
EP0756494A1 (en) * 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
JPH09503396A (ja) * 1994-07-29 1997-04-08 インノジェネティクス・エヌ・ブイ 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
CA2221269A1 (en) * 1995-05-16 1996-11-21 Lois A. Chandler Compositions containing nucleic acids and ligands for therapeutic treatment
CA2232601A1 (en) * 1995-09-22 1997-03-27 Immunomedics, Inc. Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE258599T1 (de) * 1997-02-21 2004-02-15 Genentech Inc Antikörperfragment-polymerkonjugate
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
MX2007002441A (es) 2004-08-31 2007-05-04 Pharmacia & Upjohn Co Llc Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2015006736A2 (en) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof

Also Published As

Publication number Publication date
BR0008759B1 (pt) 2014-03-11
AU2004231217B2 (en) 2008-02-28
AU2004231217A1 (en) 2004-12-23
KR100731826B1 (ko) 2007-06-22
IL144259A (en) 2009-06-15
KR20020011364A (ko) 2002-02-08
BR0008759A (pt) 2002-08-06
CN1355842A (zh) 2002-06-26
JP2014064594A (ja) 2014-04-17
ATE526401T1 (de) 2011-10-15
EP1144613B1 (en) 2011-09-28
AU775937B2 (en) 2004-08-19
JP2002534119A (ja) 2002-10-15
AU2413300A (en) 2000-08-01
IL194483A0 (en) 2011-08-01
EP1144613A1 (en) 2001-10-17
ES2373093T3 (es) 2012-01-31
EP2305804A1 (en) 2011-04-06
JP2010280714A (ja) 2010-12-16
NZ513077A (en) 2004-03-26
CA2359345A1 (en) 2000-07-20
JP5517844B2 (ja) 2014-06-11
BR122013003013B1 (pt) 2015-06-30
WO2000042175A1 (en) 2000-07-20
EP1144613B2 (en) 2020-05-06
CN1210400C (zh) 2005-07-13
EP2305804B1 (en) 2015-05-06
EP1144613A4 (en) 2002-10-29
BR122013003013B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
IL194483A0 (en) Methods for making proteins containing free cysteine residues
IL152804A0 (en) Methods for refolding proteins containing free cysteine residues
DK0469074T3 (da) Cystein-tilsatte varianter af IL-3 og kemiske modifikationer deraf
RU96115394A (ru) Производные камптотецина
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CA2064473A1 (en) Chimeric amino acids and peptides containing these analogues
NZ285132A (en) Maleimide and maleic acid derivatives; sunscreens containing michael acceptor linked directly or indirectly to a chromophore group
ATE32728T1 (de) Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel.
EP0235692A3 (en) Oligopeptidyl nitrile derivatives, the agents containing them, process for their preparation and their use
FI895921A0 (fi) Enzymhaemmande aminosyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning.
ATE377000T1 (de) 5-ht1f agonisten
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
TR200100125T2 (tr) Çok döngülü tiyazolidin-2-iliden aminleri, bunların üretimi için yöntemler
CA2199568A1 (en) Multifunctional vinyl cyclopropane derivatives
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
JPS5446776A (en) Novel peptide
DK380289A (da) Fremgangsmaade til ekstraktion af aminosyrer fra vandige oploesninger deraf
DK0408423T3 (da) Beskyttelseskompositioner for metaller, fremgangsmåder til fremstilling deraf og fremgangsmåder til beskyttelse af metaller
DE69000259D1 (de) Pharmazeutische zusammensetzung enthaltend 1-isopropyldihydrolysergsaeure.
JPS5461170A (en) Preparation of coerulein and its analogs
ATE87939T1 (de) Glycosylierte aminosaeuren und peptide.
RU99126871A (ru) Гликоконъюгаты 20(s)-камптотецина
RU2000123696A (ru) Защищенные пептиды кальцитонина